Literature DB >> 27270433

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

L A Selth1,2,3, R Das1,2,3, S L Townley1,2,3, I Coutinho1,2,3, A R Hanson1,2,3, M M Centenera2,3,4, N Stylianou5, K Sweeney5, C Soekmadji5, L Jovanovic5, C C Nelson5, A Zoubeidi6, L M Butler2,3,4, G J Goodall3,7,8, B G Hollier5, P A Gregory3,7, W D Tilley1,2,3.   

Abstract

MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely correlated with epithelial-mesenchymal transition signatures (EMT) in clinical samples and can drive mesenchymal-epithelial transition (MET) in model systems. Indeed, miR-375 potently inhibited invasion and migration of multiple prostate cancer lines. The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. Knockdown of YAP1 phenocopied miR-375 overexpression, and overexpression of YAP1 rescued anti-invasive effects mediated by miR-375. Furthermore, transcription of the miR-375 gene was shown to be directly repressed by the EMT transcription factor, ZEB1. Analysis of multiple patient cohorts provided evidence for this ZEB1-miR-375-YAP1 regulatory circuit in clinical samples. Despite its anti-invasive and anti-EMT capacities, plasma miR-375 was found to be correlated with circulating tumor cells in men with metastatic disease. Collectively, this study provides new insight into the function of miR-375 in prostate cancer, and more broadly identifies a novel pathway controlling epithelial plasticity and tumor cell invasion in this disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270433     DOI: 10.1038/onc.2016.185

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

1.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

Review 2.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

3.  Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease.

Authors:  Luke A Selth; Scott Townley; Joanna L Gillis; Aleksandra M Ochnik; Krisna Murti; Robyn J Macfarlane; Kim N Chi; Villis R Marshall; Wayne D Tilley; Lisa M Butler
Journal:  Int J Cancer       Date:  2011-11-03       Impact factor: 7.396

Review 4.  MicroRNA control of epithelial-mesenchymal transition and metastasis.

Authors:  Jinsong Zhang; Li Ma
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening.

Authors:  Sven Wach; Elke Nolte; Jaroslaw Szczyrba; Robert Stöhr; Arndt Hartmann; Torben Ørntoft; Lars Dyrskjøt; Elke Eltze; Wolf Wieland; Bastian Keck; Arif B Ekici; Friedrich Grässer; Bernd Wullich
Journal:  Int J Cancer       Date:  2011-05-09       Impact factor: 7.396

7.  Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Authors:  P M Neilsen; J E Noll; S Mattiske; C P Bracken; P A Gregory; R B Schulz; S P Lim; R Kumar; R J Suetani; G J Goodall; D F Callen
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

8.  Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.

Authors:  Mitsunori Ota; Hiroshi Sasaki
Journal:  Development       Date:  2008-11-12       Impact factor: 6.868

9.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Authors:  Manav Korpal; Brian J Ell; Francesca M Buffa; Toni Ibrahim; Mario A Blanco; Toni Celià-Terrassa; Laura Mercatali; Zia Khan; Hani Goodarzi; Yuling Hua; Yong Wei; Guohong Hu; Benjamin A Garcia; Jiannis Ragoussis; Dino Amadori; Adrian L Harris; Yibin Kang
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

10.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

View more
  46 in total

1.  Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas.

Authors:  Don L Gibbons; Chad J Creighton
Journal:  Dev Dyn       Date:  2017-05-04       Impact factor: 3.780

2.  Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Authors:  Steve Paltoglou; Rajdeep Das; Scott L Townley; Theresa E Hickey; Gerard A Tarulli; Isabel Coutinho; Rayzel Fernandes; Adrienne R Hanson; Iza Denis; Jason S Carroll; Scott M Dehm; Ganesh V Raj; Stephen R Plymate; Wayne D Tilley; Luke A Selth
Journal:  Cancer Res       Date:  2017-05-04       Impact factor: 12.701

Review 3.  The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.

Authors:  Ioanna Akrida; Vasiliki Bravou; Helen Papadaki
Journal:  Mol Biol Rep       Date:  2022-05-23       Impact factor: 2.742

Review 4.  The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms.

Authors:  Yirao Zhang; Yang Wang; Hao Ji; Jie Ding; Keming Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-06-14

5.  microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).

Authors:  Guanlin Wu; Jian Wang; Guojun Chen; Xing Zhao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

6.  Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.

Authors:  Heather H Cheng; Melissa Plets; Hongli Li; Celestia S Higano; Catherine M Tangen; Neeraj Agarwal; Nicholas J Vogelzang; Maha Hussain; Ian M Thompson; Muneesh Tewari; Evan Y Yu
Journal:  Prostate       Date:  2017-11-06       Impact factor: 4.104

7.  Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.

Authors:  Adrien Costantini; Catherine Julie; Coraline Dumenil; Zofia Hélias-Rodzewicz; Julie Tisserand; Jennifer Dumoulin; Violaine Giraud; Sylvie Labrune; Thierry Chinet; Jean-François Emile; Etienne Giroux Leprieur
Journal:  Oncoimmunology       Date:  2018-04-20       Impact factor: 8.110

8.  Mechanism of MicroRNA-375 Promoter Methylation in Promoting Ovarian Cancer Cell Malignancy.

Authors:  Junjun Shu; Ling Xiao; Sanhua Yan; Boqun Fan; Xia Zou; Jun Yang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

9.  miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Authors:  Yuan Wang; Rachel Lieberman; Jing Pan; Qi Zhang; Meijun Du; Peng Zhang; Marja Nevalainen; Manish Kohli; Niraj K Shenoy; Hui Meng; Ming You; Liang Wang
Journal:  Mol Cancer       Date:  2016-11-10       Impact factor: 27.401

10.  MiR-375 Is Epigenetically Downregulated by HPV-16 E6 Mediated DNMT1 Upregulation and Modulates EMT of Cervical Cancer Cells by Suppressing lncRNA MALAT1.

Authors:  Shikai Liu; Lili Song; Hairong Yao; Liang Zhang; Dongkui Xu; Fangyuan Gao; Qian Li
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.